Cannabis, CBD, and PLS

Cannabis is one of the most commonly asked-about symptom treatments in motor neuron disease — partly because cannabinoids have real evidence for spasticity relief in multiple sclerosis, and partly because many patients were already using it recreationally before their diagnosis. The evidence for PLS specifically is thin, but what exists is clinically useful. This page walks through what is actually known, what mechanisms explain the sometimes-confusing effects, and how to think about the tradeoffs honestly.

Why this question matters

Spasticity is the dominant symptom in Primary Lateral Sclerosis. It drives much of the stiffness, the difficulty walking, the cramping, and — indirectly — the fatigue of having to move against constant muscle resistance. The current treatments are helpful but imperfect. Baclofen and tizanidine are the mainstays, but both have a weakness-inducing side effect that some patients cannot tolerate. Intrathecal baclofen pumps are effective but invasive. Botulinum toxin injections are targeted but temporary.

Against that backdrop, patients — and clinicians — have been asking for years whether cannabinoids could fill a gap in the spasticity toolkit. The answer is nuanced: there is real evidence that they can help, there is real evidence that the wrong form can make walking dramatically worse, and the same plant can do both things to the same patient on the same day.

The evidence: CANALS and its context

The central piece of motor-neuron-disease-specific evidence is the CANALS trial (Riva et al., Lancet Neurology 2019) — an Italian multicentre, double-blind, placebo-controlled Phase 2 study of nabiximols (brand name Sativex) in 60 patients with ALS, PLS, and progressive muscular atrophy. Nabiximols is a pharmaceutical oromucosal spray containing a standardised 1:1 ratio of THC to CBD (delta-9-tetrahydrocannabinol and cannabidiol, the two main active compounds in cannabis).

CANALS found that nabiximols reduced spasticity on the Numeric Rating Scale by a statistically significant margin over placebo after six weeks of treatment. The effect was modest in absolute terms but consistent, and the drug was well-tolerated — no serious adverse events were attributed to it. A subset of PLS patients was included in the cohort, making CANALS the closest thing we have to PLS-specific cannabinoid evidence.

CANALS is the foundation, but it is not the only relevant study. The much larger evidence base comes from multiple sclerosis, where nabiximols is actually approved for spasticity in many countries (including France, the UK, Germany, Italy, and Spain). Randomised trials in MS have shown that roughly a third of patients achieve clinically meaningful spasticity reduction on nabiximols — a number large enough to justify regulatory approval. MS and PLS are different diseases, but both involve upper motor neuron damage producing the same core spasticity phenomenon, which is why the MS evidence is considered relevant by most MND clinicians thinking about cannabinoids.

Beyond spasticity, cannabinoids have evidence for pain, sleep, and appetite in various chronic conditions. These are real secondary benefits for patients living with a chronic neurological disease, though the evidence base in MND itself is thin and indirect.

Why THC can make walking worse even when it helps muscles

Here is where the picture gets clinically important. Cannabis produces two kinds of motor effects that pull in opposite directions:

The slow, chronic benefit: reduced spasticity

THC and CBD act on the endocannabinoid system, a network of CB1 and CB2 receptors expressed throughout the nervous system. In the context of spasticity, the key mechanism is CB1 activation on presynaptic terminals in the spinal cord and brainstem, which reduces the release of excitatory neurotransmitters onto motor neurons. The net effect is a dampening of the hyperexcitable output that causes spastic muscle tone. This is the mechanism CANALS was testing, and it is slow — it builds up over days to weeks of regular use. You do not feel it immediately, and you may not even register it consciously. What you notice is that your muscles are a little looser than they would otherwise be.

The fast, acute effect: impaired motor coordination

At the same time, THC — the intoxicating compound in cannabis — acts strongly on CB1 receptors in the cerebellum, basal ganglia, and motor cortex. These are the brain regions responsible for coordination, balance, motor planning, proprioception, and postural control. Acute THC exposure reliably impairs all of these functions in a dose-dependent way. This is well-documented in healthy subjects: reaction time slows, balance worsens, fine motor control deteriorates, and gait becomes less precise. In a healthy person, this is a small additional drag — most people still walk fine after smoking.

The motor reserve problem

This is the single most important point on this page. A PLS patient who smokes high-THC cannabis is experiencing both effects simultaneously: a slow, barely-perceptible reduction in spasticity, and an immediate, obvious reduction in motor coordination. The second effect is far more noticeable, which is why the dominant subjective experience is often "I can't walk as well when I smoke" even though the chronic benefit is real.

THC vs CBD — the distinction that matters

Cannabis contains dozens of active compounds, but two of them dominate the clinical picture:

• THC (delta-9-tetrahydrocannabinol) is the intoxicating compound. It produces the "high," and it produces the acute motor impairment described above. It also contributes to the spasticity benefit — the CANALS trial used a 1:1 THC:CBD ratio because both compounds have muscle-relaxing effects. But THC is the compound responsible for the walking problem.
• CBD (cannabidiol) is not intoxicating. It does not produce acute motor impairment at ordinary doses. It has its own modest evidence for spasticity reduction, probably through allosteric modulation of CB1, effects on TRPV1 and 5-HT1A receptors, and downstream inflammatory pathways. The spasticity evidence for pure CBD is weaker than for nabiximols, but it is real and it is growing.

This distinction is why pharmaceutical nabiximols uses a 1:1 ratio: it is a compromise designed to deliver the spasticity benefit of both compounds while minimising the psychoactive burden of pure THC. Recreational cannabis, by contrast, is usually bred for high THC and minimal CBD — the worst possible ratio for someone trying to manage spasticity without acute motor impairment. Modern recreational strains often have THC levels of 15-25% and CBD levels below 1%.

For a PLS patient thinking about cannabinoids for spasticity, the clinically sensible option is typically a CBD-dominant product with minimal or no THC, or a 1:1 pharmaceutical preparation like nabiximols where it is available. This delivers the chronic spasticity benefit without the acute motor hit that makes walking worse.

The withdrawal question after decades of daily use

Many PLS patients were using cannabis recreationally long before their diagnosis — often for decades. When someone in this situation stops, either on advice or because the walking issue became too obvious, something important can happen: the first few weeks of abstinence may feel like the disease getting worse.

This is not necessarily disease progression. Cannabis withdrawal syndrome is a well-documented clinical entity (it is in the DSM-5 as Cannabis Withdrawal Disorder), and after decades of daily heavy use, withdrawal symptoms are almost universal. They include:

• Increased anxiety and irritability
• Sleep disturbance (particularly for the first 1-2 weeks)
• Decreased appetite
• Restlessness and inner tension
• Increased muscle tension and discomfort — directly relevant to spasticity baseline assessment

This last point matters. If a long-term user stops cannabis and their spasticity feels worse, it may be genuinely worse (the cannabis was helping more than they realised), or it may be withdrawal-related muscle tension, or both. Withdrawal symptoms typically peak in the first week and resolve over 2-4 weeks, so waiting a month before drawing conclusions about the "true" spasticity baseline is reasonable. During that window, short-term support from first-line spasticity medications (baclofen or tizanidine, if not already in use) can bridge the gap.

Putting it together: practical options

Someone with PLS who has been using cannabis daily and is now noticing that it impairs walking has a few reasonable paths:

1. Stop completely. Accept a few weeks of withdrawal symptoms, then assess the true spasticity baseline without any cannabis at all. Add or adjust standard spasticity medications as needed. This is the cleanest diagnostic approach, but it asks for 2-4 weeks of discomfort.
2. Switch to a CBD-dominant product with little or no THC. This preserves the chronic spasticity benefit of cannabinoids while eliminating the acute motor impairment. A reasonable starting point is to replace recreational cannabis with a standardised CBD oil and dose by the label. Results take 1-3 weeks to establish, so give it time.
3. Discuss nabiximols (Sativex) with a neurologist. Where it is prescribable, nabiximols delivers a standardised 1:1 ratio with pharmaceutical quality control. Some MND specialists will prescribe it off-label for spasticity in severe cases. It is approved for MS spasticity in France and much of Europe, which makes the off-label MND conversation easier.
4. Keep recreational cannabis but time it around mobility needs. This is the honest "harm reduction" path. If a patient wants to continue using recreational cannabis, the acute motor impairment lasts for several hours after each use, so planning walking and mobility activities during drug-free periods is a partial solution. Not ideal, but realistic for patients who are not willing or able to stop.

In all four paths, the conversation worth having is with a neurologist who understands both MND and the cannabinoid evidence base. This is not universal — many neurologists have not read CANALS and may reflexively discourage any cannabis use — but some will engage with it seriously, and that engagement matters.

Honest caveats

The evidence base in MND specifically is thin. CANALS was a small Phase 2 trial, 60 patients, 6 weeks of treatment. The effect size was modest. There are no dedicated PLS trials, no long-term safety data in PLS, and no studies looking at cannabinoid interactions with baclofen, tizanidine, or intrathecal baclofen therapy. The effect of chronic cannabis use on MND progression is unknown. There is no evidence that cannabis (of any form) slows or modifies the underlying disease — only that it can provide symptomatic benefit for spasticity and potentially for pain, sleep, and appetite.

There are also real downsides to chronic cannabis use that this page should name. Long-term heavy cannabis use is associated with cognitive effects that matter especially in the context of the ALS-FTD spectrum: even though PLS is not directly linked to cognitive decline the way ALS is, anything that adds cognitive load in an older patient with a progressive neurological disease deserves careful thought. Cannabis can also paradoxically worsen anxiety in some people, can interact with sleep architecture in ways that reduce deep sleep, and creates dependence with its own withdrawal profile. None of this is a reason to rule out cannabinoids — it is a reason to think carefully about the form, the dose, and the reason for use.

What to ask your doctor

A natural experiment — and what it points to

There is a less obvious use of the cannabis observation that is worth naming explicitly. When a PLS patient experiences a dramatic, reproducible acute worsening of walking after THC exposure, the finding is not just a "watch out for side effects" moment. It is a natural pharmacological experiment that tells us something specific about the circuits his remaining walking ability depends on. THC is a partial agonist at CB1 cannabinoid receptors, which are densely expressed in the cerebellum and basal ganglia — the motor circuits that compensate for damaged corticospinal output in PLS. If THC knocks out those circuits and walking collapses, the circuits in question are carrying a disproportionate share of the load, and compounds that enhance those same circuits (rather than the damaged corticospinal tract itself) become the most mechanistically targeted options.

The Targeting Compensatory Motor Circuits in PLS page walks through the full reasoning chain and names the specific compounds that emerge from it — most notably dalfampridine (Fampyra), which directly enhances cerebellar Purkinje cell output, and ropinirole (Adartrel), which was shown to slow ALS progression in the 2023 Keio University ROPALS trial and enhances basal ganglia motor output. If the cannabis observation on this page is one that resonates with your experience, that is the page to read next.

How this connects

This page sits inside the investigational treatments section because cannabinoids are not an approved therapy for PLS spasticity. It connects directly to the main spasticity management page, which covers baclofen, tizanidine, intrathecal baclofen, and botulinum toxin as the established first-line options. The underlying research is collected on the spasticity research hub, and the key trial — CANALS 2019 — has its own dedicated study page. For a fuller honest picture of what else is tried off-label for PLS symptoms, see off-label medications. And for the mechanistic reasoning that starts from the acute THC effect and points toward specific compensatory-circuit compounds, see Targeting Compensatory Motor Circuits.

This page is not medical advice. Cannabis use — recreational, medicinal, or pharmaceutical — should be discussed with a qualified neurologist who knows your full clinical picture.